Advertisement

Search Results

Advertisement



Your search for all items matches 19626 pages

Showing 201 - 250


Arti Hurria, MD, FASCO

The oncology community was deeply saddened by the untimely passing of Arti Hurria, MD, FASCO, a nationally regarded expert and advocate for elderly patients with cancer. Dr. Hurria died on November 7, 2018, in a traffic accident. At the time of her tragic death, Dr. Hurria was Director of the City...

An Aspiring Musician Changes Course and Becomes a Breast Cancer Specialist Who Makes Music

Internationally renowned breast cancer expert, Larry Norton, MD, FASCO, spent his formative years in a Long Island town that rubbed shoulders with the border of New York City. Making music was Dr. Norton’s first passion and a cheap subway ride landed him in Greenwich Village, the Holy Grail of the ...

Ahead of the Curve, Breast Cancer Specialist Advocates Prevention Through Exercise and Lifestyle

Breast cancer specialist Julie Gralow, MD, FASCO, Director, Breast Medical Oncology, Seattle Cancer Care Alliance, has a straightforward philosophy about her career: “Cancer is about living, not dying. I enjoy helping my patients with breast cancer take control of their health through leading-edge ...

News From the Centers for Medicare & Medicaid Services

The Centers for Medicare & Medicaid Services (CMS) recently issued final rulings on several issues relevant to prescription drug prices and Medicaid provider payments. Prescription Drug Prices On May 16, 2019, CMS issued a final rule that modernizes and improves the Medicare Advantage and Part ...

New Data on Improving Access to Cancer Care, Advances in Precision Medicine Highlighted at 2019 ASCO Annual Meeting

As this special edition of The ASCO Post goes to press, more than 32,000 cancer experts from around the world have convened in Chicago to share the latest clinical cancer research impacting patient care at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO). Advances in...

Never Forgetting His Roots Helps Surgical Oncologist Better Connect With His Patients

  Raja M. Flores, MD, grew up in New York’s Meatpacking District, a rough West Side neighborhood, light years before its gentrification into a hip commercial area, home to the Whitney Museum of American Art, high-end designer clothing stores and chic bars, and a stretch of the High Line (an...

ASCO Honors Leaders in Cancer Care With 2019 Special Awards

ASCO and ASCO’s Conquer Cancer Foundation are proud to recognize the winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards and Tribute Award. The recipients of these awards have worked to transform cancer care around the world. Don’t miss the opportunity...

From the Lab to the Clinic to the Sea: Balancing a Challenging Career

Internationally recognized breast cancer expert Lisa A. Carey, MD, FASCO, was born in New Jersey and moved to Montreal, where she attended an all-girls school (Miss Edgar’s and Miss Cramp’s School for Girls)  until age 8. When she was 9 years old, her father’s business ventures took the family back ...

A Lifetime Dedicated to Patients With Lung Cancer

Former ASCO President Paul Bunn, Jr, MD, FASCO, was born at the New York Hospital, the second oldest hospital in New York City and the third oldest in the nation. He grew up in DeWitt, New York, an eastern suburb of Syracuse, and went through the public-school system graduating from...

A Brilliant Career in Oncology Decided on a Coin Toss

Rajendra Achyut Badwe, MBBS, MS, was born and reared in the sprawling city of Mumbai, the most populous city in India. “My grandmother was a matron in an infectious disease hospital. At that time, smallpox was a serious issue, and the patient care challenges were momentous. She taught me the value...

lung cancer
immunotherapy

Addition of Bevacizumab to Carboplatin/Pemetrexed in Nonsquamous NSCLC

New research published by Bagley et al in JNCCN—Journal of the National Comprehensive Cancer Network used a large real-world data set to demonstrate a modest but consistent survival benefit associated with adding bevacizumab to carboplatin/pemetrexed in advanced nonsquamous non–small...

issues in oncology

Median Lag Time for First-in-Human to First-in-Child Oncology Trials

Cancer drugs approved by the U.S. Food and Drug Administration (FDA) took a median of 6.5 years to advance from the first clinical trial in adults to the first trial in children, according to a study published by Neel et al in the European Journal of Cancer. “Despite knowing that these...

lymphoma
immunotherapy

Polatuzumab Vedotin and Immunochemotherapy in Previously Untreated Diffuse Large B-Cell Lymphoma

As reported in The Lancet Oncology, Tilly et al found that the combination of polatuzumab vedotin, an antibody-drug conjugate targeting the CD79b component of the B-cell receptor, with immunochemotherapy showed high response rates in the phase II portion of a phase I/II study in previously...

bladder cancer
immunotherapy

CheckMate 032: Extended Follow-up of Nivolumab and Nivolumab/Ipilimumab Cohorts in Previously Treated Metastatic Urothelial Carcinoma

As reported in the Journal of Clinical Oncology by Sharma et al, follow-up of the cohort receiving nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg the phase I/II CheckMate 032 trial showed the regimen produced high levels of activity in platinum-treated, unresectable, locally advanced or metastatic ...

breast cancer

GeparSepto: Long-Term Clinical Outcomes With Neoadjuvant Nab-paclitaxel vs Solvent-Based Paclitaxel in Early Breast Cancer

As reported in the Journal of Clinical Oncology by Untch et al, long-term follow-up in the GeparSepto trial showed that patients with early breast cancer receiving neoadjuvant nab-paclitaxel vs solvent-based paclitaxel followed by epirubicin/cyclophosphamide had better invasive disease–free...

Stand Up To Cancer Names Grant Recipients of ‘Innovation in Collaboration’

The Phillip A. Sharp Awards for Innovation in Collaboration, are named for Phillip A. Sharp, PhD, Nobel Laureate, and molecular biologist at Massachusetts Institute of Technology, in recognition of his emphasis on collaboration across research institutions and different teams. Stand Up To Cancer...

Radiation Oncologist Lori J. Pierce, MD, FASCO, FASTRO, Enjoys Balancing Administrative and Clinical Roles

Lori J. Pierce, MD, FASCO, FASTRO, grew up in Washington, DC, and moved with her family to Philadelphia while in high school. She still considers the fast-paced DC–Philadelphia corridor her home, but her passion for a career in medicine, in part, took seed in a small town located in North...

Nearly 25 Oncology Practices Achieve ASCO’s QOPI Certification to Date in 2019

The American Society of Clinical Oncology, Inc. (ASCO®) commends the 24 practices that took their standard of care to the next level and achieved Quality Oncology Practice Initiative (QOPI®) Certification in the first quarter of this year. By electing to go through the certification process, these...

breast cancer
issues in oncology
global cancer care

Breast Cancer Specialist Focuses on Educational Side of Oncology, Connecting Patients With Cancer Around the World

Internationally renowned breast cancer specialist Daniel A. Vorobiof, MD, was born in Santa Fe, Argentina, a province in the northeastern region of the country that is prone to catastrophic flooding. Asked about any early influences in his desire to pursue a career in medicine, Dr. Vorobiof...

AACR Announces Three Distinguished Public Service Award Recipients

The American Association for Cancer Research (AACR) presented the Distinguished Public Service Award to three individuals for their work in preventing and curing all cancers through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research at ...

AACR Inaugurated New Leadership at 2019 Annual Meeting

The American Association for Cancer Research (AACR) inaugurated Elaine R. Mardis, PhD, as President for 2019–2020 during the 2019 AACR Annual Meeting. Dr. Mardis holds the Nationwide Foundation Endowed Chair in Genomic Medicine and is Co–Executive Director of the Institute for Genomic Medicine at...

James P. Allison, PhD

James P. Allison, PhD, is Chair of Immunology and Executive Director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center in Houston. In 2018, Dr. Allison received the 2018 Nobel Prize in Physiology or Medicine, with Tasuku Honjo, MD, PhD, for launching an effective...

Cancer Researcher Continues to Push the Envelope in Immunotherapy to Help Patients Live Longer

Nationally regarded cancer immunologist Padmanee Sharma, MD, PhD, was born and reared in Georgetown, Guyana, on South America’s North Atlantic coast, noted for being the only South American country in which English is the official language. Her parents were descendants of indentured immigrants...

2019 Fellows of the American Society of Clinical Oncology (FASCO) Recognized During Annual Meeting in Chicago

The Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. The recipients of the FASCO designation were recognized during the 2019 ASCO Annual Meeting, May 31–June 4, 2019, at...

A Career Path Balancing Research, Patient Care, and Everyday Life

In elementary school, Laurie H. Sehn, MD, MPH, dreamed of becoming a teacher. However, as she moved through high school, her passion for science blossomed, as did her desire to have an impact on people’s lives. “I began to seriously consider medicine because it provided the dual opportunity to...

FDA Oncology Drug Approvals Granted Between May 21, 2018 and May 14, 2019

Over the past year (May 2018–May 2019), the U.S. Food and Drug Administration (FDA) granted approval and accelerated approval to a number of new oncology drugs and biosimilars. Here we list the new FDA-approved labels and indications. AVELUMAB (BAVENCIO) and AXITINIB (INLYTA) has been approved as a ...

lymphoma

FDA Approves Lenalidomide in Combination for Previously Treated Follicular and Marginal Zone Lymphomas

Today, the U.S. Food and Drug Administration (FDA) approved lenalidomide (Revlimid) in combination with a rituximab product for previously treated follicular and marginal zone lymphoma. AUGMENT and MAGNIFY Trials Approval was based on two clinical trials: AUGMENT and MAGNIFY. In AUGMENT, 358...

issues in oncology
survivorship

Sexual Minority Cancer Survivors and Need for Improved Access to Care

Results from a study published early by Boehmer et al in Cancer point to the need for improved access to medical care for sexual minority cancer survivors—in particular, sexual minority women. In women who are sexual minority cancer survivors, poor access to care is more strongly related to...

breast cancer

FDA Approves Alpelisib in Combination With Fulvestrant for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

On May 24, the U.S. Food and Drug Administration (FDA) approved alpelisib (Piqray) tablets to be used in combination with the FDA-approved endocrine therapy fulvestrant to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2...

breast cancer
survivorship

Risk of Subsequent Breast Cancer in Female Childhood Cancer Survivors

As reported by Ehrhardt et al in the Journal of Clinical Oncology, high doses of anthracyclines were associated with increased breast cancer risk in female childhood cancer survivors in the St. Jude Lifetime Cohort Study, with the association being independent of mutations in cancer risk...

lung cancer

FDA Approves the NovoTTF-100L System in Combination With Chemotherapy for Malignant Pleural Mesothelioma

On May 23, the U.S. Food and Drug Administration (FDA) approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable locally advanced or metastatic malignant pleural mesothelioma. NovoTTF-100L is a noninvasive,...

symptom management

FDA Approves Ruxolitinib for Acute Graft-vs-Host Disease

On May 24, the U.S. Food and Drug Administration (FDA) approved ruxolitinib (Jakafi) for steroid-refractory acute graft-vs-host disease (GVHD) in adult and pediatric patients 12 years and older. REACH1/Study INCB 18424-271 Approval was based on the REACH1 trial/Study INCB 18424-271, an...

Emily Whitehead, Early Recipient of CAR T-Cell Therapy for ALL, Celebrates 7 Years Cancer-Free

Among the success stories in the treatment of acute lymphoblastic leukemia (ALL) in children and young adults is the development of chimeric antigen receptor (CAR) T-cell therapy. The field of cellular immunotherapy was still in its infancy in 2012 when Emily Whitehead, then 7, became the first...

hepatobiliary cancer

Triplet Chemotherapy in Unresectable Locally Advanced or Metastatic Biliary Tract Cancers

In a phase II trial reported in JAMA Oncology, Rachna T. Shroff, MD, and colleagues found that the addition of nab-paclitaxel to standard gemcitabine and cisplatin resulted in promising outcomes in patients with unresectable locally advanced or metastatic biliary tract cancers. The study included...

breast cancer

Fulvestrant/Anastrozole in Metastatic Breast Cancer

As reported in The New England Journal of Medicine by Rita S. Mehta, MD, and colleagues, the final overall survival results of the phase III SWOG S0226 trial show that the addition of first-line fulvestrant to anastrozole was associated with improved overall survival in postmenopausal women with...

breast cancer

ACP Issues Guidance for Breast Screening in Average-Risk Women

AVERAGE-RISK women between the ages of 50 and 74 who have no symptoms of breast cancer should undergo breast cancer screening with mammography every other year, the American College of Physicians (ACP) has recommended in a new evidence-based guidance statement published by Qaseem et al in Annals of ...

AYA Survivors Should Be Allowed to Participate in Adult Clinical Trials

When strangers ask me how many children I have, I’m not quite sure how to respond. Do I still have four children even though one has died? A year and a half after my son Brent’s death, at the age of 18, from complications of acute myeloid leukemia (AML), I’m still struggling with knowing the...

Unlocking the Secrets of the Immune System, Story by Story

The story of immunotherapy is one of the most interesting and provocative in medical history. William B. Coley, MD, first harnessed the immune system against cancer in the late 19th century by injecting mixtures of live and inactivated bacteria into patients’ tumors. For various reasons,...

An Insider’s Account of the Nobel Prize–Winning Race to Uncover the Secret of the Ribosome

Situated in the nucleus of the human cell is DNA, the secret of life discovered by the Nobel Prize laureates Drs. Watson and Crick. More recently, another scientist, Venki Ramakrishnan, PhD, won a Nobel Prize for his work in uncovering another secret within the human cell: the structure of the...

pancreatic cancer

Expect Questions About Screening for Pancreatic Cancer

Although the detection of pancreatic cancer at early stages would offer an improved chance for successful treatment and survival, symptoms of pancreatic cancer are usually vague or absent, and screening to detect pancreatic cancer earlier is not recommended for average-risk asymptomatic patients....

pancreatic cancer

Lifestyle Modifications and Screening of Patients at High Risk Can Reduce Deaths From Pancreatic Cancer

After disclosing that he had been diagnosed with stage IV pancreatic cancer, Alex Trebek, longtime host of the popular television game show Jeopardy!, vowed that he would beat the disease despite the low associated survival rate. His statement has brought pancreatic cancer back into the public...

AACR Inaugurated New Leadership at 2019 Annual Meeting

The American Association for Cancer Research (AACR) inaugurated Elaine R. Mardis, PhD, as President for 2019–2020 during the 2019 AACR Annual Meeting. Dr. Mardis holds the Nationwide Foundation Endowed Chair in Genomic Medicine and is Co–Executive Director of the Institute for Genomic Medicine at...

cns cancers

Rookie

His steps generated a low rumble that propagated through the floor like a tsunami, flowed up through my desk, and ended as tiny waves visible through the clear plastic of my water bottle. His custom Lucchese ostrich boots made a distinctive clicking sound as they rhythmically struck the tile floor, ...

hepatobiliary cancer

FDA Approves Ramucirumab for Hepatocellular Carcinoma

ON MAY 10, the U.S. Food and Drug Administration (FDA) approved ramucirumab (Cyramza) as a single agent for hepatocellular carcinoma in patients who have an alpha fetoprotein (AFP) level ≥ 400 ng/mL and have been previously treated with sorafenib. REACH-2 Trial APPROVAL WAS based on the REACH-2...

NCCN Recognizes Five Individuals for Achievements in Cancer Care

THE NATIONAL Comprehensive Cancer Network® (NCCN®) has announced the recipients of a series of awards honoring individuals whose contributions have fueled progress in improving and facilitating quality, effective, efficient, and accessible cancer care over the past year. They are Timothy J....

Pancreatic Cancer Collective Funds Two Research Teams Using AI to Identify High-Risk Populations

THE PANCREATIC Cancer Collective, which is the strategic partnership of the Lustgarten Foundation and Stand Up To Cancer (SU2C), recently announced that it has awarded $1 million grants to each of 2 projects that are using artificial intelligence (AI) computational approaches to identify high-risk...

City of Hope Awarded $7.5 Million for Research in Cutaneous T-Cell Lymphoma

CITY OF HOPE recently received $7.5 million in grant awards to study the rare blood cancer cutaneous T-cell lymphoma. The National Cancer Institute (NCI) awarded two grants valued at $6.3 million over 5 years to City of Hope’s Steven Rosen, MD, and Christiane Querfeld, MD, PhD, so they can develop...

pain management
health-care policy

Debating the Role of Opioids in the Management of Chronic Cancer Pain

Despite the increasing public awareness of the danger of the overuse of prescription opioids, drug overdose deaths continue to rise in the United States. According to the Centers for Disease Control and Prevention (CDC), from 1999 to 2017, nearly 400,000 people died of an overdose involving...

Andrew T. Chan, MD, MPH, Receives 2019 AACR–Waun Ki Hong Award

The American Association for Cancer Research (AACR) recently awarded Andrew T. Chan, MD, MPH, with the 2019 AACR–Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research during the 2019 AACR Annual Meeting. Dr. Chan is recognized for his work on the molecular...

Miami Cancer Institute Opens Multidisciplinary Skin Cancer Clinic

Miami Cancer Institute has announced the opening of its Multidisciplinary Skin Cancer Clinic, along with the region’s first three-dimensional (3D), whole-body, photo-imaging system, designed to improve the accuracy of diagnosing melanoma and other skin cancers. This system is reportedly 1 of 12...

Advertisement

Advertisement



;
Advertisement